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In humans, HCG secreted from the implanting embryo stimulates progesterone production of 
the corpus luteum to maintain embryo implantation.  Along with this endocrine system, 
current evidence suggests that the maternal immune system positively contributes to the 
embryo implantation.  In mice, immune cells that have been sensitized with seminal fluid 
and then the developing embryo induce endometrial differentiation and promote embryo 
implantation.  After hatching, HCG activates regulatory T and B cells through LH/HCG 
receptors and then stimulates uterine NK cells and monocytes through sugar chain receptors, 
to promote and maintain embryo implantation.  In accordance with the above, the 
intrauterine administration of HCG-treated PBMC was demonstrated to improve implantation 
rates in women with repeated implantation failures.  These findings suggest that the maternal 
immune system undergoes functional changes by recognizing the developing embryos in a 
stepwise manner even from a pre-fertilization stage and facilitates embryo implantation in 







 The mammalian female evolved to utilize the uterus to receive embryo implantation.  
Consequently, it had to evolve to interact with the implanting embryo in the female genital 
tract and adapt maternal organs to accept the embryo in the uterus.  To achieve this 
adaptation, a new endocrine organ developed, the corpus luteum (CL), which is periodically 
transformed from the ovulated follicles in the ovary, and utilizes a CL-produced hormone, 
progesterone, that induces suitable endometrial differentiation for embryo implantation1.   
 On the other hand, since Wegmann proposed the immunotrophic hypothesis2, it has 
been gradually accepted that there are certain immune cell populations that positively play an 
important role in embryo implantation from the very early stage of pregnancy.  Current 
evidence suggests that immune cell contribution at the implantation site is important for 
successful embryo implantation3-5.  We have also provided evidence to support that immune 
cells in the blood circulation positively regulate the CL function and endometrial 
differentiation to promote subsequent embryo implantation6.  In this article, we describe dual 
regulation by endocrine and immune systems, focusing on the positive contribution of the 
immune system to embryo implantation in cooperation with the endocrine system. 
 
Dual positive control of CL function by endocrine and immune systems 
 
 In 1994, Espey proposed that ovulation is an inflammatory reaction caused by 
various proteolytic enzymes such as serine proteases and metalloproteases7. After ovulation, 
human granulosa cells transform into large luteal cells, undergoing luteinization to produce 
progesterone, while theca interna cells become small luteal cells, producing androgen that is 
converted into estrogen.  We previously confirmed the differential functions of luteinized 
granulosa and theca interna cells in vitro8, and the individual differentiation pathways, 
identifying differentiation markers9-11.  Along with the luteinizing process, endothelial cells 
migrate into the granulosa cell layer and construct a new vascular network12.  Luteinizing 
granulosa cells were demonstrated to produce several angiogenic factors such as vascular 
endothelial growth factor (VEGF), angiogenin, endocrine gland-VEGF, and angiopoietin13-16. 
A suitable synchronization between luteinization and neovascularization is necessary to 
establish a mature CL, and this maturation process should be further synchronized with 
endometrial differentiation in order to timely receive and support the implantation of the 
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developing embryo.  The functional lifespan of the human CL continues only for 14 days 
when embryo implantation does not occur17.  However, when implantation is successfully 
achieved, the CL of the menstrual cycle is further transformed into the CL of pregnancy to 
supply progesterone.  
 Luteinizing hormone (LH) and human chorionic gonadotropin (HCG) are key 
hormones to regulate the CL formation, transformation to the CL of pregnancy, and 
maintenance of the function.  Both hormones share the same receptor, the LH/HCG receptor.  
We immunohistochemically confirmed that LH/HCG receptor expression on luteal cells is 
maintained in the CL of pregnancy, while its expression disappears in the regressing CL18.  
HCG promotes progesterone8 and VEGF production19 by luteal cells, indicating that LH/HCG 
is a major factor to induce luteinization and neovascularization in the CL (Figure 1).   
 Previously, we reported that interleukin-1 inhibits LH-induced luteinization of 
porcine granulosa cells in vitro20, proposing a dual control of the cyclic ovarian function by 
endocrine and immune systems21.  Later, we demonstrated that PBMC, especially T 
lymphocytes, enhance progesterone production by cultured human luteinizing granulosa 
cells22, and that cytokines regulate their luteinization23.  Furthermore, these cytokines, but 
not HCG, were shown to enhance the luteinization-associated expression of dipeptidyl 
peptidase-IV that can degrade chemokines on the cell surface24.  These findings suggest that 
the circulating immune cells physiologically contribute to the luteinization process of human 
granulosa cells during CL formation25.  
 After successful implantation, HCG secreted from the implanting embryo induces 
transformation of the CL of the menstrual cycle into the CL of pregnancy.  In contrast, 
clinical evidence suggests the presence of different mechanisms to regulate the human CL of 
pregnancy26.  However, no soluble factor other than HCG has been identified27.  To identify 
new mechanisms, we raised monoclonal antibodies and found that HLA-DR, LFA-3/CD58, 
and ALCAM/CD166, which mediate interaction with T lymphocytes, were expressed on the 
human luteal cells28,29.  These findings led us to the new concept that immune cells are 
involved in the transition into the CL of pregnancy and its functional regulation.  
Accordingly, we hypothesized that signals from the developing embryo in the genital tract are 
transmitted to the ovary by not only the endocrine system, but also the immune system, in 
other words, not only soluble factors, but also circulating immune cells6,29.   
 To evaluate the above theory, we examined the effects of PBMC on progesterone 
production by the luteal cells isolated from the human CL.  In contrast to the long-standing 
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concept that immune cells enhance CL regression30, PBMC isolated from pregnant women 
were shown to promote progesterone production.  In the same co-culture, the production of 
Th-2 cytokines, IL-4 and IL-10, was increased and these cytokines significantly enhanced 
progesterone production by human luteal cells31, suggesting that circulating blood immune 
cells during early pregnancy promote CL function32 (Figure 1).   
 In the cow, it was reported that the populations of residual CD8αα+ and γδ+CD8αα+ 
T cells were significantly increased during CL regression along with a decrease in the 
proportion of FOXP3+ lymphocytes.  In contrast, there was an increase in the CD8αβ+ and 
γδ+CD8αβ+ populations within the CL of early pregnancy33.  Currently, it is being proposed 
that immune cells modulate both luteotropic and luteolytic processes34. 
 
Dual positive control of endometrial function and differentiation by endocrine and immune 
systems 
 
 Recently, gene knockout techniques confirmed that progesterone critically induces 
endometrial differentiation and decreases the contractility of uterine smooth muscle cells to 
promote embryo implantation1,35.  By the sequential administration of estradiol and 
progesterone, waves of human uterine contraction from the fundus to cervix were induced by 
estradiol, but were immediately diminished after the administration of progesterone36, 
providing supporting evidence that progesterone is an essential hormone to maintain the 
pre-implantation embryo in the uterine cavity.     
 In humans, endometrial decidualization is induced by progesterone.  In 1991, we 
reported that interleukin-1 inhibits progesterone-induced decidualization on human 
endometrial stromal cells, being the first to demonstrate that cytokines can regulate human 
endometrial differentiation37.  Thereafter, accumulating evidence demonstrated that cytokine 
networks play important roles in endometrial differentiation and embryo-maternal 
cross-talk38-42. 
 Recently, Treg cells were demonstrated to promote maternal immune tolerance and 
play critical roles in embryo implantation and fetal development43.  In mice, seminal fluid 
and sperm cause the expansion of a CD4(+)CD25(+)FOXP3(+) Treg cell population in the 
para-aortic lymph nodes after coitus and the subsequent accumulation of Treg cells in the 
uterus before embryo implantation44.  It was also reported that Treg cells were rapidly 
recruited to para-aortic lymph nodes and activated in the first few days after embryo 
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implantation45.  Importantly, the exposure of the maternal immune system to seminal fluid 
was demonstrated to promote embryo implantation by activating inflammatory and inducing 
immunological changes in the female reproductive tract that facilitate embryonic development and 
endometrial receptivity46,47.   
 Intriguingly, we found that the systemic administration of splenocytes derived from 
early pregnant mice (pregnancy day 4) induced successful implantation in pseudopregnant 
recipient mice that received blastocyst transfer on pseudopregnant day 248.  To examine the 
effect on endometrial differentiation, we used a delayed implantation model in which 
pseudopregnant mice were treated with daily progesterone supplementation after oophorectomy 
on post-ovulatory day 3.  In this model, intrauterine transferred blastocysts remain floating in the 
uterine cavity.  The subsequent administration of estrogen induces blastocysts to restart 
implantation along with the expression of leukemia inhibitory factor (LIF) in the uterus49, which is 
an essential cytokine for embryo implantation50,51. Notably, the intravenous administration of 
splenocytes derived from early pregnancy induced LIF expression in the uterus and restarted 
embryo implantation without estrogen administration52.  These findings indicate the presence of 
the dual control of endometrial differentiation before embryo attachment via the endocrine and 
immune systems (Figure 1). 
 In contrast to pregnant mice, splenocytes derived from pseudopregnancy day 4 mice 
did not significantly expand the implantation window48,52.  Since the immune system of 
pseudopregnant recipient mice that had been mated with vasectomized male mice was already 
sensitized with the seminal plasma component of seminal fluid, it is reasonable to speculate that 
the presence of developing embryos in the Fallopian tube and uterus induce additional changes in 
the maternal immune function to facilitate embryo implantation.  Although the key signals from 
the developing embryo remain under investigation, several factors such as early pregnancy factors 
that inhibit T-cell-induced rosette formation, just after fertilization53, embryo-specific peptides, 
pre-implantation factors (PIF), from the two-cell stage54, and degradation products of zona 
pellucida glycoprotein, from fertilization to hatching55, have been proposed as embryonal signals 
conveyed to the maternal immune system from the developing embryo before implantation stages.  
Taken together, it is reasonable to propose that there are step-by-step mechanisms to recognize 
pregnancy by the maternal immune system prior to embryo implantation (Figure 2).     
 
Endocrine control of immune cell function and differentiation  
 
 7 
 It is generally accepted that ovarian sex steroids are important regulators of the 
function and population of immune cells in the maternal uterus3.  The immune-endocrine 
interaction is considered to suppress adverse maternal immune responses and promote 
immunotolerance pathways, contributing to fetal survival56.   
 Progesterone regulates the immune cell function by producing mediators such as the 
progesterone-induced blocking factor (PIBF) that induces Th2-dominant cytokine 
production57 and glycodelin A that protects the embryo from maternal immune attack by 
reducing the monocyte function58.  Nuclear progesterone receptor knockout mice revealed 
that progesterone antagonizes the estrogen-induced recruitment of macrophages and 
neutrophils into the uterus59.  In humans, CD56(high+)CD16(-) uterine natural killer (NK) 
cells are the predominant population in the decidual tissues during the late secretory phase of 
the menstrual cycle and early pregnancy.  Uterine NK cells were reported to interact with 
extravillous trophoblasts and contribute to the remodeling of endometrial spiral arteries60,61.  
Since the expression level of progesterone receptors on uterine NK cells is very low62, the 
progesterone-induced endometrial environment is a key factor for the in situ proliferation or 
differentiation of uterine NK cells and reprogramming of their chemokine receptor 
profiles63,64.  Progesterone has also been reported to reduce the antigen-presenting capacity 
of dendritic cells, monocytes, and macrophages and induce the recruitment of regulatory T 
(Treg) cells, contributing to the local accumulation of pregnancy-protective cells60 (Figure 1).   
  More than 40 years ago, crude HCG purified from urine was demonstrated to 
suppress immune reactions, leading to the proposal of the involvement of HCG in maternal 
immune tolerance to the fetus65.  However, immunosuppressive effects were not observed in 
highly purified HCG66, and the effects of HCG on the immune cell function subsequently 
remained controversial for a long time.  Previously, we found that recombinant-HCG 
induced the activation of NF-κB and promoted IL-8 production by human CD14-positive 
monocytes at relatively high concentrations of more than 10 IU/mL67.  However, the cell 
surface expression of LH/HCG receptors on monocytes was not observed.  Intriguingly, this 
HCG-induced IL-8 production was inhibited by an exogenous excess of D-mannose.  These 
findings suggest that HCG regulates the PBMC function through sugar chain receptors, which 
is a primitive regulatory mechanism in the immune system67.  In addition, HCG stimulated 
human PBMC to produce chemoattractants and enhance invasion by BeWo cells, a cell line 
derived from human choriocarcinoma-derived cells68.  This hormone also stimulated human 
PBMC to enhance murine blastocyst attachment and spreading69.  From these findings, we 
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proposed that HCG stimulates maternal immune cells at the implanting site through a lectin–
glycan interaction, which, in turn, promotes embryo attachment and invasion based on 
cooperation between the endocrine and immune systems32.   
 Later, a high concentration of HCG was demonstrated to regulate uterine NK cell 
proliferation.  This effect was mediated via mannose receptors rather than by LH/HCG 
receptors that were not expressed70.  The sugar chains of HCG purified from urine are 
largely cleaved before urine production71.  Accordingly, this may explain the previous 
discrepancy in the effects on immune cells between crude HCG and highly purified HCG67.  
This mechanism can partially explain the reason why such a high concentration of HCG is 
necessary to maintain a normal pregnancy67.   
 On the other hand, it was reported that LH/HCG receptors are expressed on Treg 
cells, and that HCG secreted from human trophoblast induces Treg cell migration to the 
trophoblast60.  Based on the subsequent experiments, HCG was proposed to play a central 
role in pregnancy-induced immune tolerance72.  Recently, CD19+CD24(high+)CD27+ 
regulatory B cells were reported to increase in the first trimester of pregnancy and that the 
population in patients suffering from spontaneous abortions remain as low as in non-pregnant 
women73.  This type of regulatory B cells was also demonstrated to express LH/HCG 
receptors and produce IL-10 on stimulation with recombinant HCG, suggesting the positive 
effects of HCG on regulatory B cells73,74.  
 Accordingly, HCG is currently considered to play an important role as a modulator 
of the immune function during pregnancy75.  Considering that the sugar chain system needs 
a high concentration of HCG, it is also speculated that there are two-step processes of immune 
cell sensitization by HCG, where the maternal immune system firstly responds to a normal 
range of HCG through LH/HCG receptors, and then responds to a high concentration of HCG, 
which is a reliable sign indicating the adequate development of the implanting embryo, 
through sugar chain receptors6,67 (Figure 2).   
 In accordance with the above concept, we observed that an excessive reaction of 
immune cells to HCG could induce the high-level local production of VEGF, leading to 
ovarian hyperstimulation syndrome (OHSS)76.  Consequently, this novel mechanism should 
also be investigated from a pathological perspective.      
 
Clinical approach to infertile patients applying positive immune control mechanism  
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 To examine the direct roles of immune cells in human endometrial receptivity, we 
developed an embryo attachment assay.  This assay showed high attachment rates between a 
human choriocarcinoma-derived BeWo cell mass and endometrial epithelial cells derived 
from the mid-luteal phase, and that co-culture with autologous PBMC increased attachment 
rates in the endometrial epithelial cells derived from late proliferative and early secretory 
phases77.  These findings suggest that autologous PBMC derived from non-pregnant women 
contain populations that promote endometrial cell receptivity.  In accordance with these 
findings, we observed that thymocytes derived from immature non-pregnant female mice 
induce LIF expression and embryo implantation in the delayed implantation model78, 
indicating that even with a non-pregnant status, certain T-cell populations can induce 
endometrial differentiation and promote embryo implantation. 
 Recently, implantation failure has become one of the most difficult problems that must 
be overcome in IVF therapy.  It should be noted that IVF therapy skips a large part of the 
maternal immune recognition process involving the developing embryo in the female genital 
tract.  Accordingly, we supposed that supplementation of the recognition process by the 
immune system can improve the implantation outcome, and have developed a novel therapy 
using autologous PBMC.  Briefly, PBMC are isolated from the patients and incubated with 
HCG in order to activate them for 2 days.  Thereafter, the activated PBMC are administered 
into the uterine cavity to induce adequate endometrial differentiation.  Three days later, 
blastocysts are transferred into the uterine cavity.  We applied this treatment to patients with 
4 or more repeated IVF therapy failures and found that PBMC treatment effectively improved 
the pregnancy and implantation rates79.  Later, the intrauterine administration of autologous 
PBMC without HCG treatment was also demonstrated to improve implantation rates of 
patients with no less than 3 repeated implantation failures80.  However, this therapy did not 
improve the outcome in the population without repeated implantation failures.  On the other 
hand, this approach was applied to domestic animals, and was found to improve embryo 
implantation rates81.  In addition, the intrauterine administration of PBMC derived from 
non-pregnant mice prior to embryo implantation was reported to enhance endometrial 
receptivity and promote embryonic implantation in mice with the dysfunction of embryo 
implantation82.  Very recently, the intrauterine administration of autologous PBMC was 
shown to improve clinical outcomes of patients with repeated implantation failures83.  
Furthermore, a recent study showed that the intrauterine administration of 
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corticotropin-releasing hormone (CRH)-treated autologous PBMC can improve clinical 
pregnancy rates of women with repeated implantation failure84. 
 Several mechanisms relevant to this procedure can be proposed as follows.  Firstly, 
PBMC may induce endometrial differentiation that facilitates embryo attachment. Secondly, 
although PBMC are autologous cells from the patient, the induction of PBMC by themselves 
is expected to lead to favorable inflammatory reactions in the uterine cavity in vivo.  Thirdly, 
PBMC can secrete proteases that may effectively change the function or structure of surface 
molecules expressed on endometrial luminal epithelial cells.  Fourthly, PBMC can move 
from the uterine cavity toward the endometrial stromal tissue, creating a leading pathway for 
subsequent embryo attachment and invasion.  Finally, HCG or CRH-treated PBMC 
contribute to creating a favorable immune environment for embryo implantation85.   
 A recent study suggested that patients with repeated implantation failure have 
pre-conceptional endometrial deregulations, including cell-mediated immune response86.  
Consequently, it is an important issue to develop an effective pre-evaluation method to 




 In conclusion, we described a current novel concept whereby immune cells receive 
information about the presence of a developing embryo in the female genital tract and 
transmit this information through the blood circulation to the uterus, inducing endometrial 
functional changes or differentiation, and facilitating embryo implantation in cooperation with 
the endocrine system  (Figure 1).  Accumulating evidence has led to a novel concept that 
there are step-by-step mechanisms to recognize pregnancy by the maternal immune system from 
prior to fertilization to after embryo implantation (Figure 2).  When the endocrine mechanism 
does not adequately operate, alternative mechanisms by the immune system can be clinically 
applied to infertility therapy.  Although the efficacy of this clinical approach needs more 
accurate evaluation, further clarification of the mechanisms of maternal immune cell 
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Figure 1.  Proposed dual positive regulation of CL function and endometrial differentiation 
by the endocrine and immune systems. 
 The maternal immune system recognizes the presence of a developing and 
implanting embryo in the Fallopian tube and uterus due to embryo- and species-specific 
signals such as seminal fluid, early pregnancy factor, degraded products of zona pellucida 
glycoprotein, pre-implantation factors, and/or HCG.  Affector immune cells transmit this 
information to the lymphoid organs, and then effector immune cells move to the ovary and 
endometrium via blood circulation to regulate the CL function and induce endometrial 
differentiation.  
 
Figure 2.  Step-by-step recognition of the embryo by the maternal immune system. 
 Although the key signals from the developing embryo remain under investigation, 
several factors such as seminal fluid (directly after intercourse), early pregnancy factors (EPF, 
directly after fertilization), pre-implantation factors (PIF, from the two-cell stage), degradation 
products of zona pellucida glycoprotein (ZP-DP, from fertilization to hatching), HCG through 
LH/HCG receptors (HCG-R, after hatching), and HCG through sugar chain receptors (SC-R, 
after implantation) have been proposed as embryonal signals conveyed to the maternal 
immune system from the developing embryo before implantation stages.  Proposals of the 
above signals have given rise to a novel concept that there are step-by-step mechanisms to 
recognize pregnancy by the maternal immune system prior to embryo implantation.  


